Clinical Trial Detail

NCT ID NCT01831089
Title Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors PharmaMar
Indications

head and neck cancer

breast cancer

ovarian cancer

female reproductive organ cancer

lung non-small cell carcinoma

lung small cell carcinoma

Therapies

Bevacizumab + Lurbinectedin + Paclitaxel

Lurbinectedin + Paclitaxel

Age Groups: adult senior

No variant requirements are available.